At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
Benralizumab +1 moredrug
Likely dose
Benralizumab 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis: A Phase II Randomized Placebo Controlled Trial
In Brief
A Phase 2 clinical trial evaluating Benralizumab and Placebo for Chronic Rhinosinusitis (Diagnosis) and 2 related conditions. Completed, enrolled 33 participants across 1 site.
Detailed Summary
Benralizumab will be used in a placebo controlled randomized study to treat severe chronic rhinosinusitis with nasal polyps
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedMar 2018
Primary CompletionJan 2020
Study CompletionFeb 2020
TodayJul 2026
First PostedMar 1, 2018
Enrollment StartJul 1, 2017
Primary CompletionJan 1, 2020
Study CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.3 years ago
Interventions
Benralizumabdrug
30mg Benralizumab will be delivered subcutaneously
Placebodrug
Subcutaneous placebo injection